Pulmatrix has announced a planned merger with biopharma Cullgen, which is developing oral protein degraders for the treatment of various indications. In anticipation of the merger, Pulmatrix says that it will divest inhalation assets, including PUR1800 inhaled dry powder narrow spectrum kinase inhibitor, PUR3100 inhaled dry powder DHE, and patents related to the … [Read more...] about Pulmatrix agrees to merge with Cullgen and will divest inhalation assets
Business
ALK acquires rights to ARS’s neffy adrenaline (epinephrine) nasal spray in much of the world
Danish pharma company ALK says that it is paying ARS Pharmaceuticals $145 million up front and up to $320 million in potential milestone payments plus royalties for the rights to neffy intranasal adrenaline (epinephrine) everywhere except the US, Australia, New Zealand, Japan, and China. In addition to the marketing rights to neffy for the treatment of anaphylaxis, … [Read more...] about ALK acquires rights to ARS’s neffy adrenaline (epinephrine) nasal spray in much of the world
Polyrizon raises $4.2 million for continued development of its intranasal hydrogels
Intranasal hydrogel maker Polyrizon announced that it has closed a $4.2 million IPO, with a possibility of the total rising to $4.82 million if Aegis Capital exercises an option to purchase additional shares. Polyrizon said that funds from the IPO will be used for development of its hydrogel products for nasal drug delivery, called Capture and Contain (C&C), a … [Read more...] about Polyrizon raises $4.2 million for continued development of its intranasal hydrogels
AuraVax gets BARDA contract to test its NanoSTING-002 mucosal adjuvant with Codagenix’s intranasal flu vaccine
AuraVax Therapeutics announced that the US Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA) has awarded the company a preclinical research contract to support evaluation of AuraVax's NanoSTING-002 mucosal adjuvant with Codagenix's intranasal live attenuated influenza virus (LAIV). In early 2021, AuraVax announced … [Read more...] about AuraVax gets BARDA contract to test its NanoSTING-002 mucosal adjuvant with Codagenix’s intranasal flu vaccine
Vaxinano raises €6 million for development of intranasal vaccines
French vaccine developer Vaxinano announced that it has raised €6 million to support clinical development of several intranasal vaccine candidates based on the Stellar-NP nanoparticle platform. The company's pipeline includes nasal vaccines against zoonotic diseases and parasites such as leishmaniasis and toxoplasmosis, with the majority of Vaxinano's vaccines … [Read more...] about Vaxinano raises €6 million for development of intranasal vaccines
Agomab raises $89 million for development of candidates including AGMB-447 inhaled ALK5 inhibitor for IPF
Agomab Therapeutics said that it has closed an $89 million Series D financing round that will support development of several candidates, including its AGMB-447 inhaled ALK5 inhibitor for the treatment of idiopathic pulmonary fibrosis (IPF). New investors participating in the round included Sanofi and private equity investor Invus. In December 2023, Agomab … [Read more...] about Agomab raises $89 million for development of candidates including AGMB-447 inhaled ALK5 inhibitor for IPF
Honeywell announces agreement to supply HFO 1234ze for DevPro albuterol MDI, spin off of the advanced materials business
Honeywell announced that it has signed a long-term supply agreement with DevPro Biopharma related to the use of Honeywell's Solstice Air HFO-1234ze in DevPro's DP007 albuterol metered dose inhaler. Earlier this year, DevPro and CDMO Bespak announced that they were collaborating on development of the LGWP propellant MDI. Recipharm, which later spun out Bespak, and … [Read more...] about Honeywell announces agreement to supply HFO 1234ze for DevPro albuterol MDI, spin off of the advanced materials business
Liquidia acquires additional rights to Pharmosa’s liposomal treprostinil inhalation suspension
Liquidia Corporation will pay Pharmosa $3.5 million up front plus as much as $157.75 million in milestone payments to extend their existing agreement related to L606 inhaled liposomal treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The deal also includes a license … [Read more...] about Liquidia acquires additional rights to Pharmosa’s liposomal treprostinil inhalation suspension
InCarda says development of FlecIH-103 flecainide inhalation solution will continue despite early termination of Phase 3 trial
According to InCarda, data from the Phase 3 RESTORE-1 trial of FlecIH-103 flecainide inhalation solution for aroxysmal atrial fibrillation (PAF), which was initiated in July 2022, support continued development despite the early termination of the study due to disappointing efficacy and plasma concentrations. InCarda cites delivery problems with the jet nebulizer used … [Read more...] about InCarda says development of FlecIH-103 flecainide inhalation solution will continue despite early termination of Phase 3 trial
ARS launches Neffy nasal epinephrine nasal spray in the US
ARS Pharmaceuticals has launched Neffy epinephrine nasal spray in the US, the company said. In Auguest 2024, Neffy was approved by the FDA for the treatment of anaphylaxis in patients who weigh 30 kg or more. Earlier this month, ARS submitted an sNDA for a lower dose of Neffy for the treatment of anaphylaxis in children weighing 15 to 30 kg (33-66 lbs). European … [Read more...] about ARS launches Neffy nasal epinephrine nasal spray in the US